Sirolimus-eluting and paclitaxel-eluting stents for the treatment of coronary bifurcations

详细信息    查看全文

• 作者：Azeem Latib ; John Cosgrave ; Cosmo Godino ; Asif Qasim ; Simon J. Corbett ; Davide Tavano ; Nuccia Morici ; Nicole Cristell ; Alaide Chieffo ; Mauro Carlino ; Matteo Montorfano ; Flavio Airoldi ; Antonio Colombo
• 刊名：American Heart Journal
• 出版年：2008
• 出版时间：October 2008
• 年：2008
• 卷：156
• 期：4
• 页码：745-750
• 全文大小：124 K

文摘

Background

The aim of the study was to compare the outcomes of sirolimus-eluting (SES) and paclitaxel-eluting (PES) stent implantation in coronary bifurcations treated with either a 1-stent or 2-stent strategy.

Methods

The study used a retrospective cohort analysis of consecutive de novo bifurcations, excluding left main, treated with SES or PES between April 2003 and June 2005.

Results

We identified 170 bifurcations in 161 patients treated with SES and 119 bifurcations in 112 patients treated with PES. During a median follow-up of 1,061 days (interquartile range 814-1,314), 43 patients (26.7 % ) in the SES group and 28 (25.0 % ) in the PES group had a major adverse cardiac event (P = .78). The angiographic restenosis rate per bifurcation was 20.9 % and 25.9 % , respectively (P = .41). There was no difference overall in the occurrence of target lesion revascularization (TLR) per bifurcation, 22 with SES (12.9 % ) and 18 with PES (15.1 % ), P = .61. The TLR rate was similar for SES and PES in bifurcations treated with 1 stent (6.7 % vs 11.4 % , P = .40) and in bifurcations treated with both branch stenting (20.0 % vs 20.4 % , P =1.0).

Conclusions

In this cohort, the long-term clinical outcomes appear similar overall between SES and PES in the treatment of coronary bifurcations irrespective of whether a 1-stent or 2-stent strategy was used.